Designation underscores the potential of this chemically induced, off-the-shelf cell therapy to address a high unmet need in ...
As of Thursday, January 08, Century Therapeutics, Inc.’s IPSC share price has surged by 30.65%, which has investors ...
Zacks Investment Research on MSN
Fast-paced momentum stock Century Therapeutics (IPSC) is still trading at a bargain
Momentum investors typically don't time the market or "buy low and sell high." In other words, they avoid betting on cheap stocks and waiting long for them to recover. Instead, they believe that ...
Cellistic has unveiled three new GMP manufacturing platforms designed to advance iPSC-derived cell therapies across ...
Alongside the complete kit, TheWell Bioscience has released the RocketCell (TM) iPSC Xeno-Free Growth Medium. Available as a standalone product, this xeno-free medium is designed for researchers who ...
MONT-SAINT-GUIBERT, Belgium--(BUSINESS WIRE)--Cellistic, a cell therapy platform provider that partners with therapeutic developers to ensure cell therapies can achieve their full potential, has ...
Century Therapeutics Inc. Annual stock financials by MarketWatch. View the latest IPSC financial statements, income statements and financial ratios.
Neurodegenerative diseases affect about 15 % of the global population and are on the rise due to aging demographics. Neuroinflammation, driven by the brain’s immune cells known as microglia, is a key ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback